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The expression of various bone morphogenetic proteins,
receptors and signalling molecules in several human can-
cers could be shown, but little is known about the connec-
tion between BMP expression and clinical parameters and
outcome. In vitro experiments demonstrated that bone
morphogenetic proteins exhibit supporting and suppress-
ing actions during tumor formation and progression. We
could previously show that BMPs affect different tumor
associated processes like apoptosis, cell cycle and differen-
tiation in breast carcinoma cells depending on the time of
exposure (Steinert et al., 2008). These results encouraged
us to investigate the clinical relevance of BMP in breast
cancer patients.
We used tissue microarray technology to determine the
BMP-2 expression in over 2000 specimen from breast can-
cer patients via immunochemistry. Furthermore we ana-
lyzed proteins that are involved in tumor-associated
processes like apoptosis. The results were tested for signif-
icant correlations to histopathological parameters and
overall survival.
The immunohistochemical investigations demonstrated a
weak to moderate expression of BMP-2 in 60% of the ana-
lyzed breast cancer specimen. Small, low-grade tumors
exhibited a pronounced BMP-2 expression. The BMP-2
content showed an inverse correlation to the estrogen-
receptor (p = 0.001) and to the proliferation (p = 0.001).
The BMP-2 expression is positively correlated to the anti-
apoptotic protein bcl2 (p = 0.024). The cell cycle regula-
tors cyclin D1 (p = 0.001), p27 (p = 0.029) and p16 (p =
0.003), which inhibit the G1/S-phase transition, are sig-
nificantly associated with BMP-2. In addition BMP-2 is
positively correlated to the expression of SFRP1 (p <
0.001), a Wnt-antagonist which is supposed to be a tumor
suppressor. The most prominent result was, that BMP-2
expressing tumors exhibited a significant increase in over-
all survival (p = 0.001). Grouping of the specimen accord-
ing to clinical and immunohistochemical aspects showed
a prognostic benefit of patients with a higher BMP-2 level
especially for nodal-negative invasive-ductal breast carci-
nomas.
In conclusion, BMP-2 could be identified as an independ-
ent prognostic marker for human breast cancer.
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